Phase I study of oral azacitidine plus salvage chemotherapy in relapsed/refractory diffuse large B-cell lymphoma.
Combining oral azacitidine with salvage chemotherapy is feasible and safe for aggressive lymphoma patients preparing for transplant.
This Phase I trial evaluated oral azacitidine combined with R-ICE salvage chemotherapy in relapsed/refractory DLBCL based on the rationale that hypomethylation can reverse chemotherapy resistance. Dose-finding results establish safety/feasibility data for this epigenetic sensitization strategy in DLBCL eligible for autologous transplant.
What the study was
- Study design
- Phase I clinical trial
- Population
- Relapsed/refractory DLBCL patients eligible for ASCT
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Annals of Hematology
Why it surfaced
Novel epigenetic sensitization strategy for r/r DLBCL using oral azacitidine + R-ICE; Phase I establishes safety foundation for future efficacy studies.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.